Chafic Karam, MD
Professor of Clinical Neurology
Neuromuscular Fellowship Director, University of Pennsylvania
Neurology CME course director, University of Pennsylvania
Chief, Neuromuscular Division, University of Pennsylvania
Department: Neurology
Contact information
3400 Spruce St., 3 West Gates
Philadelphia, PA 19104
Philadelphia, PA 19104
Office: 2156153751
Fax: 2153495579
Fax: 2153495579
Publications
Education:
MD
St Joseph University, 2006.
MD
St Joseph University, 2006.
Post-Graduate Training
Intern, Hotel Dieu de France, 2006-2007.
Intern, Mount Sinai Beth Israel, 2007-2008.
Resident in Neurology, Mount Sinai Beth Israel, 2008-2011.
Fellow in Neuromuscular Disorders, Harvard Neurology at Brigham and Women's Hospital and Massachusetts General Hospital., 2011-2012.
Fellow in Peripheral Nerve Disorders, Mayo Clinic, 2012-2013.
Intern, Hotel Dieu de France, 2006-2007.
Intern, Mount Sinai Beth Israel, 2007-2008.
Resident in Neurology, Mount Sinai Beth Israel, 2008-2011.
Fellow in Neuromuscular Disorders, Harvard Neurology at Brigham and Women's Hospital and Massachusetts General Hospital., 2011-2012.
Fellow in Peripheral Nerve Disorders, Mayo Clinic, 2012-2013.
Certifications
American Board of Psychiatry and Neurology, Neurology Certificate No. 56979 , 2011.
American Board of Psychiatry and Neurology Neuromuscular Medicine Certificate No. 557 , 2012.
United Council for Neurologic Subspecialties Clinical Neuromuscular Pathology Certification , 2015.
Permanent linkAmerican Board of Psychiatry and Neurology, Neurology Certificate No. 56979 , 2011.
American Board of Psychiatry and Neurology Neuromuscular Medicine Certificate No. 557 , 2012.
United Council for Neurologic Subspecialties Clinical Neuromuscular Pathology Certification , 2015.
Description of Clinical Expertise
CIDP, MMN, Amyloid Neuropathy.Selected Publications
Hsu RT, Wilson J, Karam C. : Amyloid Spikes on Optical Coherence Tomography Demonstrating Ocular Involvement in ATTRv Amyloidosis Neurology. May 2025.Bril V, Drużdż A, Grosskreutz J, Habib AA, Kaminski HJ, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Gayfieva M, Greve B, Woltering F, Vissing J; MG0004 study investigators. : Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. J Neurol. March 2025.
Morganroth J, Karam C. : Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments Neurol Clin Pract. Feb 2025.
Rebello, S., Hsu, K., Nativi-Nicolau, J., Karam, C., Grogan, M., Lousada, I., & Maurer, M. S. : Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey. Amyloid 1–10, Feb 2025.
Qarni TN, Jones FJS, Drachman B, Khella S, Pieretti J, Bustamante NS, Karam C. : Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study Orphanet J Rare Dis. May 2024
Karam C. : Navigating the switch from IVIG to FcRn inhibition in CIDP: Clinical insights. J Neurol Sci. 2024 Dec 16;468:123354. J Neurol Sci. 468(123354), December 2024.
Bhatt K, Delgado DH, Khella S, Bumma N, Karam C, Keller A, Rosen AM, Bozas A, Shea A, Towne MC, Polfus LM, Kaeser GE, Sanjurjo V, Shah KB. : Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program. J Am Heart Assoc. 2024 Nov 22:e033770. Nov 2024.
Karam C, Moffit C, Summers C, Merkel MP, Kochman FM, Weijers L, Puls M, Schurer M, Jones E, Mason N, Finkel M, Schmitt P, Hanna M.: The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement. Orphanet J Rare Dis. Nov 2024.
Jones FJS, Zager E, Karam C. : Clinical Reasoning: A 61-Year-Old Man With Progressive Right Leg Numbness and Weakness. Neurology. 2024 Oct 22;103(8):e209900 October 2024.
Suhr, O. B., Grogan, M., Silva, A. M. da, Karam, C., Garcia-Pavia, P., Drachman, B., … Kinney, G. G. : PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid. 2024 Oct 29:1-8. Oct 2024.